Overview
- The board approved the plan on July 21 and the company disclosed it in a regulatory filing on July 27, with implementation starting this year and largely complete by the end of 2029.
- Boston Scientific estimates pre-tax charges of $700 million–$800 million, of which about $600 million–$700 million will be cash outlays, and expects roughly $500 million in annual savings when fully implemented.
- The plan centers on supply‑chain optimization and shifting production between factories to lower costs and redeploy resources into priority growth areas.
- Management warned the changes will cause some job losses while also creating new roles in growth segments, and the filing estimates up to $300 million of the charges may relate to terminations.
- Investors are watching Q2 results due July 29 for signs the company can sustain margins and revive growth in its heart‑device business, with shares rising modestly after the restructuring disclosure.